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Objectives The goal of this study was to demonstrate superiority of sirolimus-eluting stents (SES) over bare-
metal stents (BMS) and of abciximab over no abciximab in primary percutaneous coronary intervention (PCI).
Background Drug-eluting stents (DES) are increasingly used in primary PCI, but the recommenda-
tions for use in primary PCI are based on a few randomized controlled trials with selected patients.
The usefulness of abciximab in primary PCI is not established.
Methods Nine hundred seven patients referred to the Catharina Hospital were randomized to SES
or BMS, and to abciximab or no abciximab in a prospective, randomized, open 2  2 factorial trial
with blinded evaluation. Primary endpoint was major adverse cardiac and cerebrovascular events
(MACCE), deﬁned as the composite of death, myocardial infarction (MI), stroke, repeat revasculariza-
tion, and bleeding at 1 year (stent arm) and the composite of death, target vessel MI, target vessel
revascularization (TVR), and bleeding at 30 days (abciximab arm).
Results At 1 year, the rate of MACCE was lower in the SES arm (16.5% vs. 25.8%, p  0.001), mainly
driven by less repeat revascularization (9.8% vs. 16.8%; p  0.003) and without inﬂuencing the cumula-
tive incidence of death and MI (5.2% vs. 5.8%; p  0.68). At 30 days, the rate of the composite of death,
target vessel MI, TVR, and bleeding was lower in the abciximab arm (8.2% vs. 12.4%, p  0.04), mainly
driven by less TVR due to less stent thrombosis (1.2% vs.7.4%, p  0.001). However, bleeding complica-
tions occurred more frequently in the abciximab group (5.7% vs. 2.8%, p  0.03).
Conclusions Primary PCI with SES reduces adverse events at 1 year, mainly by reduction of repeat re-
vascularization, whereas abciximab reduces early stent thrombosis, at the expense of more bleeding
complications. (Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation
Myocardial Infarction [DEBATER]; NCT00986050) (J Am Coll Cardiol Intv 2012;5:313–22) © 2012 by the
American College of Cardiology Foundation
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314In patients with ST-segment elevation myocardial infarc-
tion (STEMI), primary percutaneous coronary intervention
(PCI) with stenting is the treatment of choice (Class of
Recommendation 1, Level of Evidence: A) according to the
European guidelines (1) and the American College of
Cardiology/American Heart Association guidelines (2).
he recommendation for routine stenting in the guidelines
s based on studies that have demonstrated the usefulness of
are-metal stents (BMS) in patients with STEMI (1).
lthough drug-eluting stents (DES) have been used widely
n unstable angina and in acute myocardial infarction (MI),
heir routine use in STEMI is still a point of debate (1,3).
Randomized clinical trials and meta-analyses have shown
hat DES in STEMI and in stable patients reduce the rates
f target vessel revascularization (TVR), with a similar
ong-term incidence of death or MI (4–7). However,
oncerns remain about the long-term safety with increased
rates of late events, such as stent
thrombosis due to pathological
responses of the vessel wall to
DES, especially in acute MI (8).
DES that elute sirolimus
(SES) or paclitaxel from poly-
mer carriers have demonstrated
a reduction in TVR as compared
with BMS in stable angina or
non-STEMI patients (4,6,9).
Some studies have shown that
patients receiving SES have a
significantly lower risk of reste-
nosis, TVR, and major adverse
cardiac events compared with
patients receiving paclitaxel-
eluting stents (9,10). To date,
only a few medium-sized ran-
domized trials have compared
SES and BMS in STEMI (11,12),
nd for other DES, most studies were performed in
elected patients.
Glycoprotein IIb/IIIa inhibitors are the most potent
ntiplatelet drugs. Glycoprotein IIb/IIIa inhibitors have
een studied extensively in patients with non-STEMI
efore or after PCI (1,13). However, in studies on the
outine use of abciximab in STEMI, no uniform results
ere obtained (3). The question remains whether routine
dministration of abciximab still has additional benefits,
articularly when clopidogrel is used.
We designed the DEBATER (Comparison of Drug
luting and Bare Metal Stents With or Without Abciximab
n ST Elevation Myocardial Infarction) trial to investigate
he superiority of SES over BMS in unselected patients with
TEMI undergoing primary PCI and the superiority of
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RR  relative risk
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
TVR  target vessel
revascularizationbciximab over no abciximab in the clopidogrel era.Methods
Study design. The DEBATER trial was an investigator-
initiated, prospective, randomized, open 2 2 factorial trial
with independent data management, statistical analysis, and
blinded endpoint evaluation in patients from 10 regional
referring centers who underwent primary PCI at 1 single
PCI center. The study was initiated and coordinated by the
Catharina Hospital Eindhoven and the Department of
Biostatistics, Academic Medical Center–University of Am-
sterdam. The steering committee was responsible for the
design, conduct, and reporting of the study. Data manage-
ment and analyses were performed in collaboration with the
Academic Medical Center–University of Amsterdam (the
Netherlands). The study was approved by the institutional
review board. All the authors reviewed and edited the
manuscript, and vouch for the accuracy and completeness of
the data and the analyses.
Patient population. Patients 18 years of age or older with
TEMI were eligible if they presented within 12 h of onset
f symptoms. Patients who were on oral anticoagulation and
atients who had received thrombolytic therapy or treat-
ent with a glycoprotein IIb/IIIa inhibitor in the previous
4 h were not eligible. Other exclusion criteria were con-
raindications for DES, contraindications for clopidogrel or
lycoprotein IIb/IIIa inhibitors, comorbid conditions with a
redictable fatal outcome in the short run, cardiogenic
hock, and inability to give informed consent.
Eligibility was assessed and informed consent was ob-
ained by the interventional cardiologist immediately after
he patient had arrived at the catheterization laboratory and
efore coronary angiography was performed.
Procedures. After informed consent had been obtained,
andomization was done using a 24-h computer-generated
andom-allocation system that randomly allocated patients
n a 1:1:1:1 basis to treatment with a DES or a BMS and
o treatment with abciximab or no abciximab with a factorial
esign. The DES was always a SES (CYPHER, Cordis
orporation, Bridgewater, New Jersey), whereas the choice
f the BMS was left to the discretion of the operator. All
atients received aspirin (300 mg chewed or 500 mg
ntravenously), clopidogrel (600 mg) and a fixed bolus of
ntravenous unfractionated heparin (5,000 IU) in the am-
ulance. Before angiography, all patients received an addi-
ional intravenous bolus of heparin (5,000 IU). After pri-
ary PCI, aspirin 80 mg per day was given indefinitely, and
lopidogrel was prescribed (75 mg/day) for at least 1 month
fter BMS and 6 to 12 months after SES. Patients allocated
o abciximab received a 0.25 mg/kg bolus after stent
lacement followed by an infusion of 0.125 g/kg/min for
12 h. Directly after the procedure, patients were transported
back to the referring hospital with the exception of those
who were hemodynamically unstable, who stayed in the
Catharina Hospital. These logistics of rapidly admitting
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315patients to the Catharina hospital and criteria for transport-
ing back to the referring hospital, are well defined in a
covenant between all hospitals and ambulance services
involved and is an exemplar for primary PCI in the
Netherlands (14).
Patients were followed for 1 year for adverse events by
reviewing hospital and chart records at the referring hospi-
tals, by telephone calls, and in some cases, by a written
questionnaire. If necessary, we contacted the patient’s gen-
eral practitioner. All events were adjudicated by a clinical
endpoints committee under blinded conditions.
Deﬁnitions and endpoints. The primary endpoint for the
stent comparison was defined as the composite of death, any
MI, stroke, repeat revascularization, and bleeding (MACCE)
within 1 year. Reinfarction was diagnosed on the basis of a
new episode of chest pain followed by creatine kinase or
troponin concentrations exceeding twice the upper limit of
normal or new Q waves on the electrocardiogram. Recur-
rent MI during the first 48 h was diagnosed when there was
a decrease from a previous peak value of enzyme level
followed by a subsequent rise to a level exceeding twice the
upper limit of normal. All reinfarctions were considered
related to the target vessel territory unless electrocardiogra-
phy or angiography unequivocally documented otherwise.
Stroke (ischemic or hemorrhagic) was defined as an acute
neurological event of at least 24 h of duration, with focal
signs and symptoms and without evidence supporting any
alternative explanation, confirmed by computed tomogra-
phy or magnetic resonance imaging, or by pathological
confirmation. Bleeding was defined in accordance with the
ACUITY (Acute Catheterization and Urgent Intervention
Triage strategY) trial criteria as the occurrence of any of the
following: intracranial bleeding, retroperitoneal bleeding,
intraocular bleeding, access site hemorrhage requiring sur-
gery or a radiological or interventional procedure, reduction
in hemoglobin concentration of 4 g/dl, reoperation for
bleeding, or use of any blood product transfusion (15).
Secondary endpoints were death and MI and the individual
components of the primary endpoint within 1 year. Stent
thrombosis was a secondary endpoint.
For the abciximab comparison, the primary endpoint was
the composite of death, MI (target vessel related), TVR,
and bleeding within 30 days.
TVR was defined as any ischemia-driven repeat PCI of
the target vessel or bypass surgery of the target vessel. The
target vessel was defined as the entire major coronary vessel
of the culprit lesion. For the 30-day window, we also
evaluated the occurrence of bleeding and stent thrombosis.
Stent thrombosis was defined as the definite or probable
occurrence of a thrombotic event, according to the Aca-
demic Research Consortium classification (16).
Statistics and data analysis. Analysis was performed on an
intention-to-treat basis. We calculated that, with 2  427
patients in the stent comparison, the study had 85% powerto detect a significant decrease in the primary endpoint from
17% to 10%. For the abciximab comparison, the study had
80% power to show a significant decrease in the primary
endpoint from 4% to 1% with 2  424 patients. Statistical
analysis was done with SPSS (version 17.0, IBM, Armonk,
New York).
Time-to-first-event distributions were plotted as Kaplan-
Meier curves, and the log-rank test was used for compari-
son. Event rates at 30 days and 1 year were estimated from
the Kaplan-Meier curves. We present Kaplan-Meier curves
for the overall groups defined by the stent randomization
and by the abciximab randomization, after statistical tests
(logistic regression analysis) had confirmed the assumptions
of no interaction between the stent intervention and the
abciximab intervention. Relative risks (RR) were calculated
by dividing the Kaplan-Meier estimated rate of an event in
the SES or abciximab group by that in the BMS or no
abciximab group, respectively. The 95% confidence interval
(CI) for the relative risk was calculated using the standard
errors from the Kaplan-Meier curve. The significance of
differences in event rates between treatment groups was
assessed using the log-rank test.
Categorical variables were expressed as frequency (per-
centage) and were compared using the chi-square or Fisher
exact test as appropriate. Continuous variables were ex-
pressed as means and standard deviations and were com-
pared using an unpaired t test or the Mann-Whitney U test.
A 2-tailed value of p  0.05 was considered to indicate
statistical significance. Because the 30-day endpoints related
to the abciximab randomization were different in timing and
mechanism from the 12-month endpoints related to the
stent randomization, we did not apply statistical corrections
for multiple comparisons based on the stent and abciximab
randomizations.
Results
Baseline characteristics and angiographic ﬁndings. The trial
profile is displayed in Figure 1. From January 2006 to May
2008, 2,977 patients from 10 regional centers were referred
to the Catharina hospital for primary PCI for STEMI. Out
of a total of 2,977 patients presenting with an acute
STEMI, 907 were included in the study and randomly
assigned to 1 of the 4 previously described groups. Reasons
why patients were not eligible or did not give informed
consent are mentioned in Figure 1. As a control that no bias
had occurred with respect to patients who were eligible, but
in whom no informed consent was obtained or who did not
enter the study for other reasons, baseline characteristics
were compared with the baseline characteristics of the
randomized patients. No differences in any of the baseline
characteristics (demographic data, risk factors, electrocar-
diographic and angiographic data at presentation, and time
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316intervals) were present between these groups. In 35 of the
randomized patients, no PCI was performed for reasons
mentioned in Figure 1. None of these patients received
abciximab. In case a SES could not be implanted, implan-
tation of a BMS was allowed.
Baseline characteristics of all groups were well matched
(Table 1). Medication during hospitalization was well
matched, but in 55 patients assigned to no abciximab, the
operator decided to treat with abciximab for clinical reasons
in accordance with the guidelines. The median age of
patients was 60 years, and 76% of the patients were men.
There were slightly more inferior wall MIs than anterior
wall infarctions. Initial Thrombolysis In Myocardial Infarc-
tion (TIMI) flow grade 3 in the infarct-related artery was
seen in about 16% of all 4 groups. The distribution of final
TIMI flow was comparable between all groups, with 92% to
95% of patients having a TIMI flow grade 3. In 55 patients
assigned to no abciximab, the operator decided to treat with
abciximab for clinical reasons, mainly because of the occur-
Figure 1. Study Profile, Eligibility, Enrollment, and Randomization
Flow chart of the study illustrating eligibility, randomization and treatment allo
artery bypass graft; CI  contraindication; ECG  electrocardiogram; IC  info
coronary intervention; reopro  ReoPro (abciximab); SES  sirolimus-eluting s
In Myocardial Infarction.rence of distal embolization. Mean time interval from onsetof symptoms to reperfusion was 165 min and was similar in
all groups (Table 1).
Clinical outcomes: comparison of SES with BMS. Table 2
shows the clinical outcomes at 1 year for patients random-
ized to SES or BMS. Kaplan-Meier curves are presented in
Figure 2. The primary endpoint (a composite of death, MI,
stroke, repeat revascularization, and bleeding within 1 year)
occurred in 70 patients (16.5%) in the SES group and in 115
patients (25.8%) in the BMS group (RR: 0.64; 95% CI: 0.49
to 0.84; p  0.001) (Fig. 2). This difference was driven by
less repeat revascularizations (9.8% vs. 16.8% for SES vs.
BMS; p 0.003) (Fig. 2). All-cause mortality within 1 year
was 2.6% (11 deaths, 8 of which had cardiovascular causes)
in the SES group and 2.2% (10 deaths, 7 of which had
cardiovascular causes) in the BMS group (p  0.74). The
composite of death and nonfatal MI occurred in 22
patients (5.2%) in the SES group and in 26 patients
(5.8%) in the BMS group at 1 year (p  0.68) (Fig. 2).
The individual rates of stroke and significant bleeding
n. BA  balloon angioplasty; BMS  bare-metal stent(s); CABG  coronary
consent; OAC  oral anticoagulation agent; PPCI  primary percutaneous
; STEMI  ST-segment elevation myocardial infarction; TIMI  Thrombolysiscatio
rmed
tent(s)were also similar in the 2 groups through the 12 months
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317Table 1. Clinical and Angiographic Characteristics at Baseline and Concomitant Treatment
During Hospitalization
SES
(n  424)
BMS
(n  446)
Abciximab
(n  439)
No Abciximab
(n  434)
Clinical baseline characteristics
Age, yrs 60 11 61 11 60 10 60 12
Male 332 (78%) 336 (75%) 333 (76%) 338 (78%)
Risk factors
Diabetes 47 (11%) 41 (9%) 39 (9%) 49 (11%)
Hypertension 124 (29%) 130 (29%) 135 (31%) 121 (28%)
Hyperlipidemia 119 (28%) 124 (28%) 121 (28%) 124 (29%)
Family history of CAD/PAD 203 (48%) 215 (48%) 212 (48%) 208 (48%)
(Ex) smoking 286 (67%) 258 (58%) 271 (62%) 276 (64%)
History of CAD/PAD 63 (15%) 64 (14%) 65 (15%) 63 (15%)
Medication at admission
ACE inhibitors 227 (54%) 232 (52%) 224 (51%) 237 (55%)
Statins 234 (55%) 291 (65%) 267 (61%) 258 (59%)
Angiographic baseline characteristics
Number of vessels
1 209 (49%) 207 (46%) 204 (46%) 213 (49%)
2 136 (32%) 148 (33%) 149 (34%) 135 (31%)
3 79 (19%) 90 (20%) 85 (19%) 86 (20%)
Localization culprit lesion
RCA 187 (44%) 208 (47%) 195 (44%) 201 (46%)
LAD 162 (38%) 159 (36%) 160 (36%) 161 (37%)
LCX 73 (17%) 78 (17%) 81 (18%) 70 (16%)
TIMI ﬂow culprit lesion
Before PCI
0 266 (63%) 295 (66%) 287 (65%) 275 (63%)
1 47 (11%) 42 (9%) 37 (8%) 52 (12%)
2 41 (10%) 38 (9%) 44 (10%) 35 (8%)
3 70 (17%) 70 (16%) 70 (16%) 72 (17%)
After PCI
0 3 (1%) 5 (1%) 3 (1%) 6 (1%)
1 2 (0%) 2 (0%) 3 (1%) 1 (0%)
2 16 (4%) 27 (6%) 20 (5%) 23 (5%)
3 403 (95%) 412 (92%) 413 (94%) 404 (93%)
Concomitant treatment
NTG 266 (63%) 283 (63%) 270 (62%) 282 (65%)
Aspirin 415 (98%) 430 (96%) 430 (98%) 418 (96%)
Clopidogrel 420 (99%) 436 (98%) 435 (99%) 423 (97%)
Abciximab 227 (54%) 244 (55%) 416 (95%) 55 (13%)
Beta-blockers 378 (89%) 402 (90%) 398 (91%) 385 (89%)
UFH/LMWH 327 (77%) 327 (73%) 320 (73%) 336 (77%)
Time intervals, min
From onset of symptoms to
Arrival ambulance at patients site 57 65 55 65
Arrival at cath lab 145 149 148 147
Reperfusion 162 164 165 160
Door to reperfusion 17 15 17 13
Patients not referred back because
Hemodynamically unstable 11 10 8 13
Values are mean SD, n (%), or median. No significant differences are present between the different groups for any of the variables.
ACE  angiotensin-converting enzyme; BMS  bare-metal stent(s); CAD  coronary artery disease; LMWH  low-molecular-weight heparin;
LAD  left anterior descending coronary artery; LCX  left circumflex coronary artery; NTG  nitroglycerin; RCA  right coronary artery; PAD 
peripheral artery disease; PCI percutaneous coronary intervention; SES sirolimus-eluting stent(s); TIMI Thrombolysis InMyocardial Infarction;UFH unfractionated heparin.
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318of follow-up. Stent thrombosis occurred in 4% of the patients in
oth groups (Table 2).
Clinical outcomes: comparison of abciximab with no abciximab.
Table 3 shows the clinical outcomes at 30 days and at 1 year
or patients randomized to abciximab or no abciximab.
aplan-Meier curves are presented in Figure 3. In the
abciximab group, the primary endpoint (a composite of
death, target vessel MI, TVR, and bleeding at 30 days)
occurred in 36 patients (8.2%) randomized to abciximab and
in 54 patients (12.4%) randomized to no abciximab (RR:
0.65; 95% CI: 0.43 to 0.99) (p  0.04) (Fig. 3). The
difference in the primary endpoint was driven by TVR
because of stent thrombosis, which occurred in 4 patients
(1.0%) in the abciximab group versus 29 patients (6.7%) in
the no abciximab group (p  0.001) (Fig. 3). At 30 days,
bleeding occurred in 25 patients (5.7%) in the abciximab
group versus 12 patients (2.8%) in the no abciximab group
(p  0.03) (Fig. 3).
All-cause mortality within 1 year was 2.1% (9 deaths, 7 of
which had cardiovascular causes) in the abciximab group and
2.8% (12 deaths, 9 of which had cardiovascular causes) in the
no abciximab group (p  0.49) (Table 3). There were also no
differences in the occurrence of stroke between the 2 groups.
The lower incidence of TVR at 1 year in the abciximab
group as compared with the no abciximab group (6.6% vs.
11.1%, p  0.02) was nullified by a higher incidence of
bleeding in the abciximab group as compared with the no
Table 2. Clinical Outcome and Adverse Events: SES
Events Within 1 Year (
Primary endpoint: composite of death, MI, stroke,
repeat revascularization, bleeding
7
Death 1
Composite of death and MI 2
Stroke
Repeat revascularization 4
Target vessel revascularization 2
Nontarget vessel revascularization 1
Deﬁnite or probable stent thrombosis 1
Deﬁnite
Within 24 h
After 24 h
Interval until stent thrombosis in days
Probable
Bleeding 1
Femoral access site
Intracranial
Gastrointestinal
Pulmonary
Other
Values are n (%); % is calculated from the Kaplan-Meier curves.
CI confidence interval; MImyocardial infarction; RR relative rabciximab group (6.6% vs. 3.3%, p  0.02). Most bleedingsnvolved the femoral access site, but 1 patient had a
emorrhagic stroke and died.
iscussion
This study shows in the first place that in primary PCI in
patients with STEMI, use of SES is superior to BMS,
mainly because of a significant reduction of repeat revascu-
larization procedures within 1 year; and in the second place
that routine administration of abciximab cannot be advo-
cated in these patients because the reduction in the stent
thrombosis rate is counterbalanced by an increase in major
bleeding without a noticeable effect on overall outcome.
SES versus BMS. Our findings confirm the results of several
other studies in more selected patients, indicating superior-
ity of DES versus BMS in primary PCI. As in most of these
studies, we found that the rate of death or nonfatal MI at 1
year was not different between SES and BMS, but a
significant reduction in repeated revascularizations at 1 year
was found. This is in line with a meta-analysis by Brar et al.
(17) in 33,873 STEMI patients, showing a reduction in
restenosis rate without an increase in the incidence of death
or MI when DES was used compared with BMS.
Of note, we also found significantly more nontarget vessel
revascularizations in the BMS group, which should proba-
bly be explained by more complete revascularizations (due to
eye-balling) in patients undergoing ischemia-driven reinter-
s BMS
4)
BMS
(n  446) RR (95% CI) p Value
%) 115 (25.8%) 0.64 (0.49–0.84) 0.001
) 10 (2.2%) 1.16 (0.50–2.70) 0.74
) 26 (5.8%) 0.89 (0.51–1.57) 0.68
) 8 (1.8%) 0.53 (0.16–1.74) 0.28
) 74 (16.8%) 0.58 (0.41–0.83) 0.003
) 49 (11.0%) 0.60 (0.38–0.94) 0.02
) 33 (7.4%) 0.48 (0.26–0.87) 0.01
) 18 (4.0%) 0.99 (0.52–1.90) 0.98
16
9
7
5 5.7 2.7
2
) 24 (5.4%) 0.79 (0.43–1.43) 0.44
17
0
6
0
1
er abbreviations as in Table 1.Versu
SES
n  42
0 (16.5
1 (2.6%
2 (5.2%
4 (1.1%
1 (9.8%
8 (6.6%
5 (3.5%
7 (4.0%
14
6
8
7.7
3
8 (4.3%
14
1
1
1
1ventions (Table 2).
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319Our results extend the results of several other randomized
clinical trials in more selected patients to a general popula-
tion with STEMI (11,12,18–22). Two previous studies
with SES in STEMI are of comparable size with ours. The
TYPHOON (Trial to assess the use of the CYPHer
sirolimus-eluting coronary stent in acute myocardial infarc-
tion treated with BallOON angioplasty) study was the first
randomized clinical trial that compared SES and BMS in
712 STEMI patients and demonstrated a significant reduc-
tion in the occurrence of TVR in patients who received SES
compared with BMS (11). The trial protocol in that study
required visualization of the culprit lesion before random-
ization. Randomization was only performed immediately
after coronary angiography if the infarct-related artery was
patent or after re-establishing blood flow by the placement
of a guide wire or by balloon angioplasty. In contrast, we
included patients before angiography, avoiding any selection
bias. Our inclusion criteria are more comparable to those of
the MULTISTRATEGY (MULTIcentre evaluation of
Single high-dose Bolus TiRofiban versus Abciximab with
Sirolimus-eluting STEnt or Bare-Metal Stent in Acute
Myocardial Infarction StudY) trial. In this trial, 744
STEMI patients were randomized to SES with a high-dose
bolus of tirofiban and to BMS with abciximab. At 8
months, the rate of MACE (composite of any death,
reinfarction, and clinically driven TVR) was higher among
those who were treated with BMS (14.5%) compared with
those who were treated with SES (7.8%; p 0.004) (12). In
omparison with both trials, our rate of TVR in the BMS
roup is somewhat lower. This could explain why we found
ess reduction in the occurrence of TVR at 1 year. Further-
ore, the very strict selection criteria in the TYPHOON
rial and the shorter duration of follow-up in the MULTI-
TRATEGY study may play a role, as may the fact that our
tudy was a single-center study that included consecutive
atients with STEMI referred for primary PCI and there-
ore better reflects daily practice.
Our rate of stent thrombosis at 1 year was 4% in both
tent groups, which is in line with the results of other trials
11,21,23,24). This finding also corresponds with the results
f a more recent analysis on stent thrombosis in the
ORIZONS-AMI (Harmonizing Outcomes with Revas-
ulariZatiON and Stents in Acute Myocardial Infarction)
rial, where no relation was found between the type of stent
mplanted (DES vs. BMS) and the occurrence of stent
hrombosis up to 2 years (24).
Abciximab versus no abciximab. We found a significant
eduction in the rate of the primary endpoint (the composite
f death, target vessel MI, TVR, and bleeding at 30 days) in
atients treated with abciximab, mainly driven by a signif-
cant reduction in the need for reintervention because of
tent thrombosis. Treatment with abciximab significantly
educed the rate of stent thrombosis, without increasing 
 
Figure 2. Comparison of Outcomes in Patients Treated With SES or BMS
Time-to-event curves for the primary endpoint of death, myocardial infarc-
tion (MI), stroke, repeat revascularization, and bleeding (MACCE); the com-
posite of death and MI; and repeat revascularization at 1 year for the
sirolimus-eluting stent (SES) and the bare-metal stent (BMS). CI  conﬁ-he risk of stroke. However, treatment with abciximab
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320significantly increased the rate of bleeding complications.
Of notice, the incidence of target vessel–related MI was
much lower than the incidence of stent thrombosis,
which needs some explanation: patients with acute in-
hospital recurrent or aggravating chest pain were imme-
diately sent back to the catheterization laboratory. This
explains both the high rate of definite, angiographically
shown stent thrombosis and the low rate of early target
vessel–related MI.
A meta-analysis of the trials that have assessed the value
of periprocedural administration of abciximab in addition to
aspirin and heparin in acute STEMI showed that abciximab
reduced 30-day mortality significantly without increasing
hemorrhagic stroke and major bleedings (25,26). However,
it remained to be elucidated whether this benefit is main-
tained in patients who receive 600 mg of clopidogrel before
primary PCI. We demonstrated in our study that abciximab
started during primary PCI also provides an additional
benefit with respect to stent thrombosis in patients pre-
treated by 600 mg of clopidogrel. We have not studied the
pre-hospital or pre-catheterization use of abciximab as
studied in the FINESSE (Facilitated Intervention with
Enhanced Reperfusion Speed to Stop Events), MISSION
(Abciximab administration before primary PCI for
STEMI), and BRAVE-3 (Value of Abciximab in Patients
Table 3. Clinical Outcome and Adverse Events: Abcix
Events within 30 days
Primary endpoint: composite of death, target vessel–relat
TVR, bleeding
Deﬁnite or probable stent thrombosis
Deﬁnite
Within 24 h
After 24 h
Interval until stent thrombosis in days
Probable
Bleeding
Femoral access site
Intracranial
Gastrointestinal
Pulmonary
Other
Events within 1 yr
Composite of death, MI, stroke, repeat revascularization, b
Composite of death, MI
Stroke
Repeat revascularization
Target vessel revascularization
Nontarget vessel revascularization
Values are n (%) or n; % is calculated from the Kaplan-Meier curves.
Abbreviations as in Tables 1 and 2.With Acute MI Undergoing PCI After High Dose Clopi-dogrel Pretreatment) trials. Finally our positive results
should be set alongside the recent suggestion of bivalirudin
monotherapy as an alternative to unfractionated heparin
plus abciximab in the HORIZONS-AMI trial (27). Bivali-
rudin had a better net clinical benefit because of less severe
bleeding rates, although early thrombotic complications
were somewhat higher. In contrast, our study does show a
decrease in early thrombotic complications.
Study strengths and limitations. This study has several
specific strengths that should be mentioned. In the first
place, it is a single-center study in a high-volume center
performing approximately 1,500 primary PCIs per year.
Second, the rate of included patients is very high (36% of
all eligible patients), and the inclusion criteria were very
broad, thereby reflecting everyday practice and minimiz-
ing any possible selection bias. Third, patients were
randomized before angiography was performed. Fourth,
all baseline characteristics of eligible patients who were
not participating because of lack of informed consent or
other reasons, were not different from the randomized
patients. A limitation of the present study is the lack of
blinding of operators during primary PCI. For SES
versus BMS, such blinding is impossible. For abciximab
versus no abciximab, it could have been done. Our results
may not apply to low-volume centers and regions lacking
Versus No Abciximab
Abciximab
(n  439)
No Abciximab
(n  434) RR (95% CI) p Value
36 (8.2%) 54 (12.4%) 0.65 (0.43–0.99) 0.04
4 (1.0%) 29 (6.7%) 0.14 (0.05–0.38) 0.001
2 26
1 14
1 12
13 6.3 3.8
2 3
25 (5.7%) 12 (2.8%) 2.06 (1.05–4.05) 0.03
23 9
1 0
4 3
1 0
0 2
g 92 (21.7%) 94 (21.0%) 0.96 (0.72–1.28) 0.80
24 (5.5%) 24 (5.5%) 0.98 (0.56–1.72) 0.97
7 (1.6%) 5 (1.2%) 1.39 (0.44–4.33) 0.58
53 (12.1%) 62 (14.3%) 0.84 (0.60–1.19) 0.33
29 (6.6%) 48 (11.1%) 0.60 (0.38–0.93) 0.02
26 (6.0%) 22 (5.1%) 1.16 (0.67–2.01) 0.58imab
ed MI,
leedina well-organized referral system. Another limitation is
no abciximab. Abbreviations as in Figure 2.
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321the follow-up of 1 year, and therefore, very late stent
thrombosis, which may occur after SES implantation, is
not accounted for. Finally, newer and faster-acting thien-
opyridines could also modify the results of this study.
Conclusions
Our study shows the superiority of the drug-eluting siroli-
mus stent versus the BMS in routine unselected patients
admitted for primary PCI for acute STEMI and corrobo-
rates observations in earlier studies to the benefit of DES in
primary PCI. The benefit is mainly attributable to reduction
of repeat revascularization in the first year. Furthermore,
this study does not support routine use of abciximab in
addition to aspirin, clopidogrel, and heparin: although acute
stent thrombosis in the first 30 days was reduced, this was
accompanied by more bleeding complications, and overall
outcome at 1 year was not influenced.
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